BioSpace News Archive

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced financial results for the first quarter of 2023, and associated Company developments.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, reported financial results for the three months ended March 31, 2023.

Paratek Pharmaceuticals, Inc. reported financial results and provided an update on corporate activities for the first quarter ended March 31, 2023.

Emergent BioSolutions Inc. reported financial results for the first quarter ended March 31, 2023.

SeaStar Medical Holding Corporation announces that it has received a letter from the Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration regarding the Company’s Humanitarian Device Exemption application for its pediatric Selective Cytopheretic Device, which is designed to treat critically ill children with acute kidney injury on continuous kidney replacement therapy.

ProSomnus, Inc., a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea, announced financial results for the first quarter ended March 31, 2023.

Invitae, a leading medical genetics company, announced financial and operating results for the first quarter ended March 31, 2023.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the Company’s product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the first quarter of 2023.

Liminal BioSciences Inc. reported its financial results for the first quarter ended March 31, 2023.

Soligenix, Inc. announced the closing of its previously announced public offering of 6,538,500 shares of common stock and common warrants to purchase up to 6,538,500 shares of common stock at a combined public offering price of $1.30.